Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Cancer Type
3.3. Snippet by Stage
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Pipeline products
4.1.1.2. Improvements in Diagnosis with the Integration of Artificial Intelligence
4.1.2. Restraints
4.1.2.1. Complications related to Biopsy procedures
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Test Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
7.1.2. Market Attractiveness Index, By Test Type
7.2. Digital Rectal Exam
7.3. PSA Blood Test
7.4. Biopsy
7.4.1.1. Prostate Biopsy
7.4.1.2. Transrectal Biopsy
7.4.1.3. Transperineal Biopsy
7.4.1.4. Lymph node Biopsy
7.5. Genetic Testing
7.6. Imaging Tests
7.6.1.1. Transrectal Ultrasound (TRUS)
7.6.1.2. Magnetic Resonance Imaging (MRI)
7.6.1.3. Nuclear Imaging
7.7. Others
8. By Cancer Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.1.2. Market Attractiveness Index, By Cancer Type
8.2. Benign Prostate Hyperplasia
8.3. Prostatic Adenocarcinoma
8.4. Small Cell Carcinoma
8.5. Ductal prostate cancer
8.6. Others
9. By Stage
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
9.1.2. Market Attractiveness Index, By Stage
9.2. I
9.3. II
9.4. III
9.5. IV
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Cancer Centers
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Myriad Genetics, Inc.
13.1.1. Company Overview
13.1.2. Product Type Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Quanterix Corporation
13.3. MDx Health
13.4. Siemens Healthineers
13.5. F. Hoffman-La Roche AG
13.6. OPKO Health, Inc
13.7. Thermo Fisher Scientific Inc.
13.8. Cellanyx Diagnostics Inc.
13.9. MiR Scientific LLC
13.10. Proteomedix
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us